Saputo at Scotiabank back to school conference: bets on protein

Saputo highlighted double-digit growth in specialty whey and protein fractions, with demand still exceeding supply, while traditional cheese demand remains low-single-digit. The company is reallocating capital after exiting most of Argentina, selling its U.K. unit and monetizing an Australian minority asset for about $250 million; it also lifted its buyback authorization to 6% from 5%. Near-term pressure persists from depressed block-cheese prices and U.S. milk supply growth of 3%-4%, although management expects higher feed and energy costs to rebalance supply over 12-18 months. Fiscal 2027-28 investment will prioritize cottage cheese, cultured products, value-added milk, whey extraction and automation, with M&A limited to targeted, accretive capability or distribution additions.

Analysis

SAP’s investable change is a mix upgrade rather than a near-term dairy-cycle call. Incremental capacity in high-protein cultured dairy and specialty whey should increase the share of earnings tied to tighter, more defensible ingredient markets, while automation offers a second margin lever independent of commodity pricing. The key constraint is that specialty-whey expansion requires extraction investment and cheese throughput; this makes the opportunity real but likely back-end loaded into FY27-FY28 rather than an immediate EBITDA step-up.

The portfolio simplification should reduce earnings volatility and improve the quality of free cash flow, supporting both a higher valuation multiple and continued capital returns. However, management’s buyback authorization is not itself incremental EPS guidance: the market will require proof that divested capital earns returns above repurchases and that growth CapEx does not create excess cottage-cheese/cultured capacity after the current demand surge. A more concentrated North American/Australian footprint also leaves SAP more exposed to a synchronized milk-price and consumer-volume downturn than the historical geographic mix.

Near term, depressed cheese economics are a margin risk if higher input costs arrive before industry supply rationalizes; the stated 12-18 month adjustment window means the favorable commodity inflection is not a reliable next-quarter catalyst. Contrarian point: consensus may over-credit the protein narrative at peak ingredient pricing. The more durable upside is conversion of lower-value whey streams into specialty fractions and lower working capital through planning tools—not sustained record pricing. Watch competitor capacity announcements and realized specialty-whey spreads, as these will determine whether protein is a structural profit pool or a cyclical scarcity premium.

SAP is a restrained accumulation candidate, not a momentum trade. The stock should rerate over 6-18 months if organic growth investments lift mix and margins while net leverage stays conservative; the thesis is falsified by FY27 margin guidance failing to improve despite capacity additions, a material decline in whey pricing, or buybacks being displaced by a dilutive acquisition.

Key Decisions for Investors

• Accumulate SAP on weakness over a 6-18 month horizon; size modestly until FY27 guidance quantifies returns from protein/cultured capacity. Target a 10-15% total-return setup from mix-driven margin expansion plus capital returns; exit/reassess if FY27 EBITDA margin guidance is flat to down excluding commodity effects.
• Prefer SAP over MRU as a defensive consumer pair only if dairy ingredient spreads remain firm: long SAP / short MRU for 3-6 months. SAP has idiosyncratic mix and buyback catalysts, whereas MRU remains more exposed to food-price deflation translating into competitive retail pricing; close if relative performance widens 10% against the position or SAP reports protein-price deterioration.
• Set an alert around U.S. dairy supply, feed costs, and CME cheese/whey benchmarks rather than buying the commodity thesis today. A sustained milk-supply deceleration alongside stable specialty-whey pricing would be the cleaner catalyst to increase SAP exposure; continued supply growth with falling whey fractions would invalidate the expected mix offset.
• Do not treat BNS or BN as read-through trades. Their presence is conference/context related, and the available information provides no direct earnings mechanism for either ticker.